Browse the evidence

No significant further benefits of ingesting multi-ingredient supplements (MTN) compared to calorie equivalent comparator (COMP) supplements were identified for fat-free mass (FFM), upper-body strength, lower-body strength, and functional capacity.

Practitioners should consider that multi-ingredient supplements may not provide additional benefits over calorie equivalent supplements for body composition and performance in this population.

Obesity is a debilitating disease that requires refined, concept-driven therapeutic approaches.

Health professionals should adopt refined therapeutic approaches to address obesity.

The 'Behavioral Balance Model' integrates biological, psychological, social, economic, and environmental aspects of obesity.

Practitioners should consider a multifaceted approach to understanding and treating obesity.

Further studies are needed to investigate the safety and efficacy of glucagon and GLP-1 receptor co-agonists.

Practitioners should be aware that while glucagon and GLP-1 co-agonists show promise, more research is needed before widespread clinical application.

Adverse events from SGLT-2 inhibitors and GLP-1RAs are primarily mild to moderate and tend to subside with treatment adjustment.

Practitioners should monitor for mild to moderate gastrointestinal side effects when prescribing these medications.

Future research is needed to determine the ideal SGLT-2 inhibitor or GLP-1RA for weight loss management and the efficacy of combination therapies.

Practitioners should stay informed about ongoing research for optimal weight loss strategies using these medications.

Caution is advised when initiating GLP-1 agonist therapy in HIV patients taking protease inhibitors.

Healthcare providers should monitor HIV patients on protease inhibitors closely when starting GLP-1 agonists.

Amylin promotes satiation and recruits multiple central nervous system pathways to regulate food intake.

Understanding amylin's role can help in developing obesity treatments.

Cagrilintide, a stable amylin analogue, is under clinical development for obesity treatment.

Cagrilintide may offer a new approach to obesity management.

Nonshivering thermogenesis (NST) has potential for activating energy balance processes without significant side effects.

Practitioners may consider NST as a viable strategy for enhancing energy balance in obesity management.

Combination therapy of metabolic boosters and established anti-obesity compounds is a promising future approach.

Practitioners should explore combination therapies as a potential strategy for obesity treatment.

There was no significant relative change in disability benefit receipt for the ILI group compared to controls.

Intensive lifestyle interventions may not affect disability benefit receipt despite improving employment.

There is a surge of interest in unimolecular peptide hormone-based polypharmacy for obesity management.

Practitioners should stay informed about developments in peptide hormone therapies for obesity.

Tirzepatide is a first in class dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP) analog approved for the management of adult patients with type 2 diabetes mellitus.

Tirzepatide can be prescribed to adults with type 2 diabetes as part of their treatment plan.

Small-molecule GLP1RAs regulate both homeostatic and hedonic feeding through parallel neural circuits.

Practitioners can consider the dual impact of small-molecule GLP1RAs on different feeding behaviors.

GLP1RAs suppress the consumption of palatable foods by reducing dopamine release in the nucleus accumbens.

Understanding this mechanism can help in developing strategies to manage palatable food consumption.

Targeted deletion of the receptor in central amygdalar neurons diminishes the anorectic efficacy of GLP1RAs for reward-driven intake.

This finding highlights the importance of specific neural receptors in the effectiveness of weight loss drugs.

GIP(1-30)NH2 has similar effects on glucose and bone metabolism in healthy individuals as GIP(1-42).

GIP(1-30)NH2 may be considered a viable alternative to GIP(1-42) for influencing glucose and bone metabolism.

GIP(1-30)NH2 results in similar glucagonotropic and insulinotropic effects as GIP(1-42).

GIP(1-30)NH2 could be used similarly to GIP(1-42) in clinical settings for managing insulin and glucagon levels.

The 7-year cardiovascular risk was 17.4% in the surgery group with preoperative preparation and 18.8% in the no-surgery group, with a risk difference of -1.4.

Preoperative preparation combined with bariatric surgery does not significantly reduce cardiovascular risk.

Excessive consumption of industrial seed oils rich in linoleic acid contributes to mitochondrial dysfunction.

Reducing intake of linoleic acid-rich oils may be beneficial for mitochondrial health.

LA-induced mitochondrial perturbations are linked with gut dysbiosis.

Addressing mitochondrial health may also improve gut microbiome balance.

Strategic dietary modulation, particularly a marked reduction in LA intake, may restore mitochondrial redox homeostasis and improve metabolic health.

Reducing linoleic acid in the diet could enhance mitochondrial function and overall metabolic health.

Intestinally derived messengers, including gut hormones and microbial metabolites, regulate feeding behavior.

Understanding these signals can help in developing targeted obesity treatments.